Experimental drug combo aims to shrink Hard-to-Treat sarcomas
NCT ID NCT05711615
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or slow the disease. About 30 participants with specific sarcoma types will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Peposertib and liposomal doxorubicin
- What this could lead to
- If it works, this could point toward a new treatment option for advanced sarcomas that are hard to treat.
- What could go wrong
- This is a very early phase 1 trial with only 30 people, so it may not show benefit or could have unexpected side effects. The combination has not been proven in humans yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC DEDIFFERENTIATED LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
-
Los Angeles General Medical Center
RECRUITINGLos Angeles, California, 90033, United States
Contact Email: •••••@•••••
-
National Cancer Institute Developmental Therapeutics Clinic
RECRUITINGBethesda, Maryland, 20892, United States
-
Siteman Cancer Center-South County
RECRUITINGSt Louis, Missouri, 63129, United States
Contact Email: •••••@•••••
-
UC Comprehensive Cancer Center at Silver Cross
RECRUITINGNew Lenox, Illinois, 60451, United States
Contact Email: •••••@•••••
-
UCHealth University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
-
University of Chicago Medicine-Orland Park
RECRUITINGOrland Park, Illinois, 60462, United States
Contact Email: •••••@•••••
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
RECRUITINGMiami, Florida, 33136, United States
-
University of Michigan Rogel Cancer Center
SUSPENDEDAnn Arbor, Michigan, 48109, United States
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a personal coach at home boost energy for cancer patients?
- New PET tracer could sharpen sarcoma detection
- Engineered immune cells take aim at Hard-to-Treat cancers
- New immunotherapy targets rare cancers by harnessing the Body's immune system
- App aims to ease cancer treatment side effects
- Glow-in-the-Dark dye could help surgeons find hidden lung cancer in teens